公开(公告)号：US20100226927A1

公开(公告)日：2010-09-09

申请号：US12447634

申请日：2007-11-02

申请人： Irving L. Weissman ,  Agnieszka Czechowicz ,  Deepta Bhattacharya ,  Daniel Kraft

发明人： Irving L. Weissman ,  Agnieszka Czechowicz ,  Deepta Bhattacharya ,  Daniel Kraft

IPC分类号： A61K39/395 ,  A61K35/12 ,  A61P43/00

CPC分类号： C07K16/2896 ,  A61K35/28 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/54 ,  C07K16/2803 ,  C07K16/2812 ,  C07K16/2815 ,  C07K16/2866 ,  C07K16/32 ,  C07K2317/73 ,  C07K2317/76

摘要： The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment and tolerance.

摘要翻译： 本发明提供了一种临床适用的干细胞移植方法，其有助于移植并重建受体的免疫能力，而不需要放射治疗或化学疗法，并且不发展GVHD或移植物排斥反应。 本发明的方面基于这样的发现：内源性干细胞生态位的消耗有助于将干细胞有效植入该生态位。 特别地，本发明将内源性干细胞的选择性消融与对外源性干细胞受体的施用相结合，从而产生有效的长期植入和耐受。